Florida Financial Advisors LLC Invests $229,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

Florida Financial Advisors LLC purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 688 shares of the company’s stock, valued at approximately $229,000.

A number of other institutional investors have also recently added to or reduced their stakes in MEDP. Raymond James Trust N.A. raised its holdings in shares of Medpace by 34.6% during the 3rd quarter. Raymond James Trust N.A. now owns 754 shares of the company’s stock worth $252,000 after acquiring an additional 194 shares during the period. Swedbank AB acquired a new stake in Medpace during the third quarter worth about $7,477,000. Centaurus Financial Inc. raised its stake in Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after purchasing an additional 29 shares during the period. Fisher Asset Management LLC boosted its holdings in Medpace by 6.9% in the 3rd quarter. Fisher Asset Management LLC now owns 124,399 shares of the company’s stock valued at $41,524,000 after purchasing an additional 8,012 shares during the last quarter. Finally, Independent Advisor Alliance increased its holdings in shares of Medpace by 16.7% during the 3rd quarter. Independent Advisor Alliance now owns 941 shares of the company’s stock worth $314,000 after buying an additional 135 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $324.51 on Wednesday. The firm has a market capitalization of $9.89 billion, a PE ratio of 25.69, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The firm’s 50-day moving average is $337.16 and its two-hundred day moving average is $339.57.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on MEDP shares. Leerink Partnrs upgraded Medpace to a “hold” rating in a report on Monday. Robert W. Baird upped their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Finally, Leerink Partners initiated coverage on Medpace in a research report on Monday. They set a “market perform” rating and a $330.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $376.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.